CHMP-EMA Recommends Approval of Sarclisa (Isatuximab) as Subcutaneous Formulation Administered via On-Body Injector for Multiple Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/chmp-ema-positive-opinion-isatuximab-on-body-injector)